BINP — Bionoid Pharma Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $13.50m
- $13.60m
Annual income statement for Bionoid Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2007 December 31st | 2008 December 31st | 2009 December 31st | 2010 December 31st | 2011 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10KSB | 10-K | 10-K | 10-K | ARS |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.924 | 1.22 | 2.93 | 3.88 | 5.14 |
| Operating Profit | -0.924 | -1.22 | -2.93 | -3.88 | -5.14 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.26 | -1.59 | -3.41 | -3.91 | -5.14 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -1.26 | -1.59 | -3.41 | -3.91 | -5.14 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.26 | -1.59 | -3.41 | -3.91 | -5.14 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -1.26 | -1.59 | -3.41 | -3.91 | -5.14 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.98 | -2.36 | -3.84 | -1.57 | -3.35 |
| Dividends per Share |